The assay results indicated that the expression of basic fibroblast growth factor (bFGF, also known as FGF2) was dramatically increased in the NASH liver, which was significantly inhibited by ASTN treatment (Figure 7A, p < 0.01). This evidence concerns the gene FGF2 and metabolic dysfunction-associated steatohepatitis.